Key statistics
As of last trade, Elicio Therapeutics Inc (9HA:BER) traded at 4.18, 47.18% above the 52 week low of 2.84 set on Feb 07, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 4.18 |
---|---|
High | 4.26 |
Low | 4.08 |
Bid | 4.06 |
Offer | 4.46 |
Previous close | 4.14 |
Average volume | 0.00 |
---|---|
Shares outstanding | 10.77m |
Free float | 7.96m |
P/E (TTM) | -- |
Market cap | 49.35m USD |
EPS (TTM) | -4.83 USD |
Data delayed at least 15 minutes, as of Oct 08 2024 19:08 BST.
More ▼
Announcements
- Elicio Therapeutics Reports Inducement Grants
- Elicio Therapeutics Announces Three Upcoming Presentations Focused on its Lymph Node Targeted, mKRAS-Specific Amphiphile Vaccines
- Elicio Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
- Elicio Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Updates
- Elicio Therapeutics Announces Closing of Private Placement of $20.0 Million Convertible Note
- Elicio Therapeutics Announces Pricing of $11.5 Million Underwritten Public Offering
- Elicio Therapeutics Announces Proposed Public Offering
- Elicio Therapeutics Announces Preliminary Disease-Free Survival analysis from the Ongoing AMPLIFY-7P Phase 1a Study of ELI-002 7P
- Elicio Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
- Elicio Therapeutics Announces Publication of Preclinical Data Demonstrating TCR-T Cell Therapy in Combination with Lymph Node-Targeted Amphiphile-Immunotherapy Enhanced Anti-Tumor Function and Eradicated Solid Tumors
More ▼